Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodies

Leonardo Vargas, Nicolás Valdivieso, Fabián Tempio, Valeska Simon, Daniela Sauma, Lucía Valenzuela, Caroll Beltrán, Loriana Castillo-Delgado, Ximena Contreras-Benavides, Mónica L. Acevedo, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Rafael I. Gonzalez, Mercedes Lopez, View ORCID ProfileFabiola Osorio, María Rosa Bono
doi: https://doi.org/10.1101/2022.01.14.22269289
Leonardo Vargas
1Laboratory of Immunology, Biology Department, Faculty of Sciences, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolás Valdivieso
1Laboratory of Immunology, Biology Department, Faculty of Sciences, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabián Tempio
2Laboratory of Cancer Immunoediting, Immunology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valeska Simon
1Laboratory of Immunology, Biology Department, Faculty of Sciences, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Sauma
1Laboratory of Immunology, Biology Department, Faculty of Sciences, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucía Valenzuela
3Immunogastroenterology Lab., Gastroenterology Unit, Hospital Clínico Universidad de Chile, Facullty of Medicine, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroll Beltrán
3Immunogastroenterology Lab., Gastroenterology Unit, Hospital Clínico Universidad de Chile, Facullty of Medicine, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loriana Castillo-Delgado
4Hospital Clínico Metropolitano La Florida “Dra. Eloisa Diaz I.”, Froilan Roa 6542, La Florida, Región Metropolitana, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ximena Contreras-Benavides
4Hospital Clínico Metropolitano La Florida “Dra. Eloisa Diaz I.”, Froilan Roa 6542, La Florida, Región Metropolitana, Santiago, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mónica L. Acevedo
5Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Valiente-Echeverría
5Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo Soto-Rifo
5Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael I. Gonzalez
6Centro de Nanotecnología Aplicada, Universidad Mayor, Santiago, Chile. Center for the Development of Nanoscience and Nanotechnology, CEDENNA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mercedes Lopez
2Laboratory of Cancer Immunoediting, Immunology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mrbono@uchile.cl fabiolaosorio@med.uchile.cl melopez@uchile.cl
Fabiola Osorio
7Laboratory of Immunology and Cellular Stress, Immunology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabiola Osorio
  • For correspondence: mrbono@uchile.cl fabiolaosorio@med.uchile.cl melopez@uchile.cl
María Rosa Bono
1Laboratory of Immunology, Biology Department, Faculty of Sciences, Universidad de Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mrbono@uchile.cl fabiolaosorio@med.uchile.cl melopez@uchile.cl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Chile was severely affected by COVID19 outbreaks but was also one of the first countries to start a nationwide program to vaccinate against the disease. Furthermore, Chile became one of the fastest countries to inoculate a high percentage of the target population and implemented homologous and heterologous booster schemes in late 2021 to prevent potential immunological waning. The aim of this study is to compare the immunogenicity and time course of the humoral response elicited by the CoronaVac vaccine in combination with homologous versus heterologous boosters.

Methods and Findings We compared the immunogenicity of two doses of CoronaVac and BNT162b2 vaccines and studied the effect of different booster regimes in the Chilean population. Our results demonstrate that a two-dose vaccination scheme with CoronaVac induces lower levels of anti-SARS-CoV-2 S antibodies than BNT162b2 in a broad age range. Furthermore, antibody production declines with time in individuals vaccinated with CoronaVac and less noticeably, with BNT162b2. Remarkably, analysis of booster schemes revealed that individuals vaccinated with two doses of CoronaVac generate immunological memory against the SARS-CoV-2 ancestral strain, which can be re-activated with homologous or heterologous (BNT162b2 and ChAdOx1) boosters. Nevertheless, the magnitude of the antibody response with the heterologous booster regime was considerably higher and persistent (over 100 days) than the responses induced by the homologous scheme.

Conclusions Two doses of CoronaVac induces antibody titers against the SARS-CoV-2 ancestral strain which are lower in magnitude than those induced by the BNT162b2 vaccine. However, the response induced by CoronaVac can be greatly potentiated with a heterologous booster scheme with BNT162b2 or ChAdOx1 vaccines. Furthermore, the heterologous booster regimes induce a durable antibody response which does not show signs of decay 3 months after the booster dose.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by a grant from the COVID-19 research program of the National Agency for Research and Development (ANID), grant No 0752 (MRB, FO, ML). MRB and DS are supported by ANID/BASAL/FB210008, and FONDECYT grants No 1191438 (MRB) and 1180385 (DS). FO is supported by an International Research Scholar grant from HHMI (HHMI#55008744), a FONDECYT grant No. 1200793, and ECOS-CONICYT grant (ECOS180052). CB is supported by a FONDECYT grant No 1181699. RSR is supported by a FONDECYT grant No 1190156. FVE is supported by a FONDECYT grant No 1211547. RG is supported by FONDECYT grants No 11180557 and CEDENNA AFB180001. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Hospital Clinico Universidad de Chile approved the study on health worker personnel (Protocol ID Number 1151/20 and Protocol ID Number 074-2020). Facultad de Ciencias, Universidad de Chile (Protocol ID 2123-FCS-UCH and consent approval).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 23, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodies
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodies
Leonardo Vargas, Nicolás Valdivieso, Fabián Tempio, Valeska Simon, Daniela Sauma, Lucía Valenzuela, Caroll Beltrán, Loriana Castillo-Delgado, Ximena Contreras-Benavides, Mónica L. Acevedo, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Rafael I. Gonzalez, Mercedes Lopez, Fabiola Osorio, María Rosa Bono
medRxiv 2022.01.14.22269289; doi: https://doi.org/10.1101/2022.01.14.22269289
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodies
Leonardo Vargas, Nicolás Valdivieso, Fabián Tempio, Valeska Simon, Daniela Sauma, Lucía Valenzuela, Caroll Beltrán, Loriana Castillo-Delgado, Ximena Contreras-Benavides, Mónica L. Acevedo, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Rafael I. Gonzalez, Mercedes Lopez, Fabiola Osorio, María Rosa Bono
medRxiv 2022.01.14.22269289; doi: https://doi.org/10.1101/2022.01.14.22269289

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (240)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1420)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
  • Epidemiology (10297)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2629)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1733)
  • Health Policy (789)
  • Health Systems and Quality Improvement (673)
  • Hematology (266)
  • HIV/AIDS (565)
  • Infectious Diseases (except HIV/AIDS) (12093)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (289)
  • Neurology (2461)
  • Nursing (145)
  • Nutrition (377)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1324)
  • Ophthalmology (401)
  • Orthopedics (146)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (780)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2397)
  • Public and Global Health (5007)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (528)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (245)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)